Patent for irinotecan hydrochloride injection and its preparation

Nanjing Chenggong Pharmaceutical Co., Ltd., a subsidiary of Nanjing hi tech holding company, has applied for the invention patent "a kind of irinotecan hydrochloride injection and its preparation method", which has been authorized by the State Intellectual Property Office The patent abstract shows that compared with the prior art, the invention has the advantages of low adverse reaction, high stability, simple production method and industrial production Analysts believe that the approval of the patent will help enhance the company's competitiveness in the field of anti-cancer Data show that irinotecan is a specific drug for the treatment of advanced colorectal cancer, which is also a chemical drug approved by FDA for the first-line treatment of metastatic colorectal cancer after fluorouracil for many years Colorectal cancer is one of the most common malignant tumors in China The incidence rate is increasing obviously It has risen from 1/10000 in 70s to 2/10000 to three in the last century Currently, the incidence rate of malignant tumor is fourth In clinic, irinotecan is not only effective in the treatment of colorectal cancer, but also used in gastric cancer, lung cancer, gynecological cancer and other cancers In April 1999, irinotecan raw materials and its injection were administratively protected in China; in March 2001, irinotecan was introduced into the Chinese market under the trade name of "keputuo" As of September 2013, in the domestic sample hospital irinotecan market, "Eli" of Hengrui pharmaceutical, "yimeilin" of Qilu pharmaceutical, and "keputuo" of Pfizer pharmaceutical have formed a tripartite competition pattern According to the data, the price of "Aili" 40mg of Hengrui pharmaceutical is 950 yuan, that of "yimeilin" 40mg of Qilu pharmaceutical is 779 yuan, and that of imported "keputuo" 40mg is 1790 yuan